Presenting author

Lars Arvastson

1 presentation

• W26. Pooled individual patient data analysis of three phase 2 trials supports vasopressin V1b receptor antagonism (BH-200 250 mg BID) as an antidepressant mechanism for the treatment of major depressive disorder (MDD)

  2026 ASCP Annual Meeting